ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
PAQ Therapeutics Logo

PAQ Therapeutics

We are developing a new class of small molecule degradation therapies by expanding the ability to directly target and eliminate disease-causing entities beyond proteins. PAQ’s expert team of global scientists, entrepreneurs and world-class scientific advisors are committed to broadening therapeutic horizons driven by advances in autophagy.

Quick overview

Cambridge, United States

Founded in 2020

1-10 Employees

Startup

Additional information

Working industry

Biotechnology

Type of company

Manufacturer

Ownership structure

Privately Held

Locations

1 Headquarter

Specialised areas

Biotechnology, Health Care, Therapeutics

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

United States


Overall risk estimation:

Low


ESG country scores

The ESG Data of countries are based on public sources

Environment

D

Grade (A-E)

View details

Social

A

Grade (A-E)

View details

Governance

A

Grade (A-E)

View details

Headquarter of PAQ Therapeutics

PAQ Therapeutics operates in 1 country around the world

City: Cambridge

State: Massachusetts

Country: United States

Locations of PAQ Therapeutics

Get an overview of the locations of PAQ Therapeutics

Location

Country

State

City

Headquarter

United States

Massachusetts

Cambridge

Frequently asked questions (FAQ) about PAQ Therapeutics

Some frequent questions that have been asked about PAQ Therapeutics

The company headquarter of PAQ Therapeutics is located in Cambridge, Massachusetts, United States. It's worth noting, that the company may have more locations

As of the latest available information PAQ Therapeutics has around 1-10 employees worldwide.

PAQ Therapeutics was founded in 2020

The company PAQ Therapeutics has it's main focus in the industries of Biotechnology

Based on the founding year and the amount of employees the company PAQ Therapeutics seems to be a Startup at the current state. Note that over time that status can change

Competitors of PAQ Therapeutics

Check out some interesting alternative companies to PAQ Therapeutics

Proteovant Therapeutics's Logo

Proteovant Therapeutics

Philadelphia, United States

11-50 Employees

2021

The power of protein degradation is now being realized. This innate cellular process is responsible for maintaining protein homeostasis, and we are now exploiting it to break down the proteins that cause disease. The protein degradation opportunity is immense and reaches across a broad range of disease areas in which new and enhanced treatments are needed. Development of the best, most effective medicines for patients requires extensive biology insight, medicinal chemistry experience, drug discovery expertise and cutting-edge computational tools such as artificial intelligence and machine learning. Proteovant is leveraging targeted protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases.

Avilar Therapeutics's Logo

Avilar Therapeutics

Waltham, United States

11-50 Employees

-

We are developing ATACs (ASGPR Targeting Chimeras), a novel class of degrader designed to harness a natural endogenous process for protein degradation. We are building an organization that is taking science to new limits and has respect for everyone. We have built a bespoke, integrated, and modular drug discovery platform to enable the design and assembly of ATACs targeting a wide array of extracellular proteins.

Orum Therapeutics's Logo

Orum Therapeutics

Kazan, Russia

11-50 Employees

2016

We are pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, and thereby improve the therapeutic window of drugs. Our goal is to bring life-changing therapies to patients by combining the power of the emerging field of protein degraders with the precision of antibodies to generate a broad portfolio of highly differentiated product candidates. A portfolio of highly differentiated products combining the power of protein degraders with the precision of antibodies.

16250 - 1st TPD Europe 2020's Logo

16250 - 1st TPD Europe 2020

London, United Kingdom

1-10 Employees

-

As the industry consolidates pipelines and heads out of a turbulent 2023 market, the targeted protein degradation engine has shown no signs of slowing. Our blossoming community of degrader experts are inspiring each other to develop medicines to address patients’ unmet medical needs. Dedicated to Progressing the Field with Groundbreaking Research.

Vivoryon Therapeutics's Logo

Vivoryon Therapeutics

Halle (Saale), Germany

101-250 Employees

1997

We are focused on developing innovative small molecule-based medicines. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings.

Lycia Therapeutics's Logo

Lycia Therapeutics

San Diego, United States

11-50 Employees

2019

To that end, we are advancing an undisclosed discovery pipeline of novel LYTAC degraders toward the clinic. We are also eligible to receive over $1.6 billion in potential milestone payments based on the achievement of prespecified preclinical, development and commercial milestones, as well as tiered royalties from mid-single to low double-digits on sales resulting from the agreement. We are leveraging the flexibility of our platform to pursue targets previously considered undruggable, opening the potential for new therapeutics options for patients. We are building a stellar team, driven to pioneer breakthrough science and motivated to make a difference for patients. Protein degradation offers the potential to eliminate disease-causing proteins. The mannose-6-phosphate receptor (M6PR) is a cell-surface glycoprotein that acts as a lysosomal trafficking shuttle.